![[ Beasley Allen Law Firm Logo ]](http://www.reglan-lawyer.net/wp-content/themes/system-unity/images/logo.png){kind=logo}
FDA issues black box warning for Reglan
Medication commonly used to treat heartburn linked to permanent involuntary muscle movement
Recently the FDA required the manufacturers of the drug metoclopramide, more commonly know as Reglan, to place a black box warning on its label. A black box warning is the strongest warning that the FDA can require.
Metoclopramide increases muscle contractions in the upper digestive tract, which speeds up the rate at which the stomach empties into the intestines. It is used short-term to treat heartburn caused by gastrophageal reflux, and also used to treat slow gastric emptying in people with diabetes, a condition called diabetic gastroparesis.
However, in recent studies, it has been shown that people taking metoclopramide can develop a serious condition called Tardive Dyskinesia.
Tardive Dyskinesia is a condition in which a person develops involuntary movements of their muscles which could include lip smacking, tongue thrusting, eye blinking and bulging, head jerking, facial grimacing, puckering and pursing of the lips, and involuntary movements of the fingers.
Long-term users of the drug, and elderly patients, especially women are at an increased risk of developing Tardive Dyskinesia. There is no known cure for Tardive Dyskinesia and even after discontinuing the drug, symptoms may still persist.
The FDA has advised physicians to avoid long term use of metoclopramide except in rare cases where the benefit outweighs the risks.
Metoclopramide is available in formulations including tablets, syrups and injections, under names including Reglan Tablets, Reglan Oral Disintegrating Tablets, Metoclopramide Oral Solution, and Reglan Injections. According to the FDA, it is estimated that more than 2 million American use these products.
Free legal consultation
If you or a loved one has been injured by Reglan side effects, you may have a claim against the manufacturer. Please contact us today by filling out the brief questionnaire, or by calling our toll free number (1-800-898-2034) for a free, no-cost no-obligation evaluation of your case.
A team of researchers renowned for their work in colon cancer believe they may have found a better treatment for Barrett’s esophagus and esophageal cancer based on findings from their colon cancer research, according to 
Very low doses of inhaled carbon monoxide has been shown to reverse a serious digestive condition in diabetic mice, a finding that could give hope to millions of sufferers of diabetic gastroparesis. The findings are based on a study conducted by researchers with the Mayo Clinic and presented at last year’s Digestive Disease Week gathering.
The U.S. Fifth Circuit Court of Appeals has found in favor with a lower court that patients may sue generic drug makers under state law for failing to provide adequate warnings about potential side effects with their drugs. The ruling extends a 2009 U.S. Supreme Court ruling governing makers of name-brand drugs. The issue of whether generic drug companies should be held liable for not adequately warning consumers has divided several district courts, which can increase the odds of a Supreme Court review in the future, according to U.S. Circuit Judge 